^
    Back
    Association details:
    Biomarker:FGFR2-POC1B fusion
    Cancer:Cholangiocarcinoma
    Drug:Pemazyre (pemigatinib) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Med Case Rep
    Title:

    Durable response from fibroblast growth factor receptor inhibition in intrahepatic cholangiocarcinoma terminated by metachronous acute myeloid leukemia: a case report

    Published date:
    12/15/2023
    Excerpt:
    A 69-year-old Caucasian patient...the diagnosis of intrahepatic cholangiocarcinoma, with differentiation grade G2, was confirmed. Since it was an R0 resection of stage I tumor... DNA extraction from Maxwell® RSC DNA FFPE Kit (Promega), DNA amplification through polymerase chain reaction and analysis through capillary electrophoresis (GenomeLab GeXP of Beckman Coulter), which identified an FGFR2 translocation/fusion (FGFR2-POC1B). A targeted therapy with pemigatinib...Our patient had a durable stable disease...
    DOI:
    10.1186/s13256-023-04231-2
    Test:
    Tissue Of Origin Test Kit - FFPE